Companies touting successful treatment candidates to fight COVID-19 are in the healthcare spotlight, gaining the attention of investors. Investigational treatments are being developed at a rapid pace by numerous companies of all sizes. This includes biotech companies such as iBio (NYSEMKT: IBIO) , an innovator specializing in the manufacturing and production of antibodies and vaccines under development.
iBio's stock price spiked in July of last year following its inclusion in the Russell 2000 and Russell 3000 indexes. But shortly thereafter, investor confidence waned due to a lack of news from its COVID vaccine candidates, leading to a 75% decline in the biotech stock .
Now, a brief renewed interest from investors is the result of exclusive licensing deals and positive pre-clinical studies involving its most promising candidates. Could this be a sign of growth to come?
For further details see:
This Under-the-Radar Pharma Company Could Be a Bargain Hunter's Dream